Telesis Bio Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Public

  • Employees
  • 110

Employees

  • Stock Symbol
  • TBIO

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $0.01
  • (As of Thursday Closing)

Telesis Bio General Information

Description

Telesis Bio Inc is a synthetic biology company focused on enabling researchers to rapidly, accurately, and reproducibly build or write high-quality synthetic DNA and mRNA that is ready to use in many downstream synthetic biology-enabled markets. It manufactures and sells laboratory equipment, specifically synthetic biology instruments, reagents, and associated products and related services. Its products comprise of BioXp system, BioXp kits, Benchtop reagents and BioXp biofoundry services.

Contact Information

Formerly Known As
SGI-DNA, Codex DNA, Inc., Codex, Codex DNA Incorporated, Codex DNA Inc, Codex DNA Inc., Codex DNA, SGI-DNA, Inc.
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 10421 Wateridge Circle
  • Suite 200
  • San Diego, CA 92121-2993
  • United States
+1 (858)
Primary Industry
Discovery Tools (Healthcare)
Stock Exchange
OTCM
Vertical(s)
Corporate Office
  • 10421 Wateridge Circle
  • Suite 200
  • San Diego, CA 92121-2993
  • United States
+1 (858)

Telesis Bio Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Telesis Bio Stock Performance

As of 12-Nov-2026, Telesis Bio’s stock price is $0.01. Its current market cap is $19.5K.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.01 $0.01 $19.5K 1.22K

Telesis Bio Financials Summary

As of 30-Jun-2024, Telesis Bio has a trailing 12-month revenue of $16.3M.

In Thousands,
USD
TTM 30-Jun-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 56,549 49,146 7,048 222,317
Revenue 16,280 27,509 27,435 11,043
EBITDA (42,428) (42,236) (44,355) (36,001)
Net Income (49,540) (47,724) (48,471) (38,958)
Total Assets 52,727 70,411 81,362 116,257
Total Debt 35,553 34,380 21,427 17,322
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Telesis Bio Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Telesis Bio‘s full profile, request access.

Request a free trial

Telesis Bio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Telesis Bio‘s full profile, request access.

Request a free trial

Telesis Bio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Telesis Bio Inc is a synthetic biology company focused on enabling researchers to rapidly, accurately, and reproducibly
Discovery Tools (Healthcare)
San Diego, CA
110 As of 2024

South San Francisco, CA
 

Coralville, IA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Telesis Bio Competitors (8)

One of Telesis Bio’s 8 competitors is Twist Bioscience, a Formerly VC-backed company based in South San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Twist Bioscience Formerly VC-backed South San Francisco, CA
Integrated DNA Technologies Formerly PE-Backed Coralville, IA
Novus Biologicals Formerly PE-Backed Centennial, CO
Azenta Life Sciences Corporation Burlington, MA
GenScript Formerly VC-backed Nanjing, China
You’re viewing 5 of 8 competitors. Get the full list »

Telesis Bio Patents

Telesis Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2025269170-A1 Methods of synthesizing nucleic acid molecules Pending 09-May-2024
US-20250346886-A1 Methods of synthesizing nucleic acid molecules Pending 09-May-2024
WO-2025235935-A1 Methods of synthesizing nucleic acid molecules Pending 09-May-2024
AU-2022485012-A1 Methods of synthesizing nucleic acid molecules Pending 31-Oct-2022
EP-4612311-A1 Methods of synthesizing nucleic acid molecules Pending 31-Oct-2022 C12P19/34
To view Telesis Bio’s complete patent history, request access »

Telesis Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Telesis Bio Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Telesis Bio‘s full profile, request access.

Request a free trial

Telesis Bio Acquisitions (1)

Telesis Bio’s most recent deal was a Merger/Acquisition with Eton BioScience for . The deal was made on 10-Nov-2021.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Eton BioScience 10-Nov-2021 Merger/Acquisition Biotechnology
To view Telesis Bio’s complete acquisitions history, request access »

Telesis Bio ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Commercial Services

Industry

Rank

Percentile

Business Support Services

Subindustry

Rank

Percentile

To view Telesis Bio’s complete esg history, request access »

Telesis Bio Exits (1)

Telesis Bio’s most recent exit was on 10-Nov-2021 from Eton BioScience. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Eton BioScience 10-Nov-2021 Completed
To view Telesis Bio’s complete exits history, request access »

Telesis Bio FAQs

  • When was Telesis Bio founded?

    Telesis Bio was founded in 2011.

  • Where is Telesis Bio headquartered?

    Telesis Bio is headquartered in San Diego, CA.

  • What is the size of Telesis Bio?

    Telesis Bio has 110 total employees.

  • What industry is Telesis Bio in?

    Telesis Bio’s primary industry is Discovery Tools (Healthcare).

  • Is Telesis Bio a private or public company?

    Telesis Bio is a Public company.

  • What is Telesis Bio’s stock symbol?

    The ticker symbol for Telesis Bio is TBIO.

  • What is the current stock price of Telesis Bio?

    As of 12-Nov-2026 the stock price of Telesis Bio is $0.01.

  • What is the current market cap of Telesis Bio?

    The current market capitalization of Telesis Bio is $19.5K.

  • What is Telesis Bio’s current revenue?

    The trailing twelve month revenue for Telesis Bio is $16.3M.

  • Who are Telesis Bio’s competitors?

    Twist Bioscience, Integrated DNA Technologies, Novus Biologicals, Azenta Life Sciences, and GenScript are some of the 8 competitors of Telesis Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process